OsteoApp.ai Developing AI-Driven Bone Health Assessment

OsteoApp.ai announced a multi-center collaboration with several clinical institutions in  the US, UK and EU to develop and clinically validate OsteoApp.ai’s AI algorithms for use in rapid, high-volume detection of undiagnosed osteopenia and osteoporosis in patients during orthopedic treatment.

Central to this collaboration is OsteoApp.ai’s recently executed agreement with the Mayo Clinic Platform for access to Mayo Clinic Platform_Discover, a large set of de-identified data and analytical tools to develop AI models. In addition, OsteoApp.ai signed a know-how agreement with Mayo Clinic to securely develop and test the company’s proprietary AI products prior to deployment for multi-center clinical testing.

These tools will be clinically evaluated by orthopedic surgeons at several clinical centers. Specific focus will be on clinical utility and integration of rapid bone quality assessments and fracture risk detection into pre-operative planning workflows and subsequent outcomes for a wide range of orthopedic conditions.

Studies show that nearly one quarter of total joint replacement patients meet criteria to receive osteoporosis medications, but only 5% receive therapy preoperatively or postoperatively. This lack of preoperative osteoporosis screening and treatment may contribute to periprosthetic fracture risk and implant loosening.

OsteoApp.ai’s patented DXR-BMD technology has demonstrated, in multiple clinical trials and dozens of peer-reviewed literature citations, to substantially increase detection rates in undiagnosed patients, both prospectively during routine clinic visits and screenings, and through retrospective population health analyses. Early detection allows for earlier intervention and treatment before suffering a debilitating and costly bone fracture. The company’s software product is delivered to customers through ubiquitous installed base of x-ray PACS networks with no need for specialized equipment or complex technician training.

Earlier this year, OsteoApp.ai announced the approval of two Category III Current Procedural Terminology (CPT) code applications for use of AI in early detection of osteoporotic fracture risk by the American Medical Association. These are the first hybrid artificial intelligence CPT codes specific to digital x-ray assessment of bone strength.

“This represents not just a big step forward for OsteoApp.ai’s solution, but also a recognition by some of the leading orthopedic surgeons on the importance of risk detection in pre-operative workflows,” said Chris J. Taylor, CEO. “These partnerships along with being a Mayo Clinic Enabled Platform Partner allows us to fast-track the trust and adoption of rapid bone quality assessments through OsteoApp’s proprietary solution.”

Source: OsteoApp.ai